Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04916444
Other study ID # IRB202101156
Secondary ID OCR40846
Status Completed
Phase N/A
First received
Last updated
Start date February 7, 2022
Est. completion date December 7, 2022

Study information

Verified date December 2022
Source University of Florida
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

We will apply 16 sessions of rTMS over 4 consecutive days for adult patients suffering from cervical dystonia who receive botox on a regular basis. The TMS protocol will take place 9 weeks following their last botox injection. The primary outcome measure will be improvement in cervical dystonia as measured by the TWSTRS scale. The secondary outcome measures include mood, cognition, gait, TMS measures, and high-density EEG measures.


Description:

This is a crossover study design in which patients will be randomized to active or sham stimulation during session 1 (S1) and then crossover to the condition they were not randomized to at first during session 2 (S1). Patients who are receiving botox for cervical dystonia on a regular basis but having benefit from botox for 9 weeks or less will be eligible to participate. The total study protocol will take place over 24 weeks. During week 1, patients will have their regularly scheduled botox injections. During week 9, patients will undergo either active or sham rTMS, as detailed below. They will have outcome measures obtained at week 9 (S1:T0; baseline/pre-TMS), week 10 (S1:T1; post-TMS), and week 12 (S1:T2; 2 weeks post-TMS). At week 12, they will undergo their regularly scheduled botox injections. During week 21, patients will undergo either active or sham rTMS, whichever condition they were not randomized into during the first session. They will have outcome measures obtained at week 21 (S2:T0; baseline/pre-TMS), week 22 (S2:T1; post-TMS), and week 24 (S2:T2; 2 weeks post-TMS). The neurostimulation protocol will be as follows: The dPMC target will be defined as 1 cm medial and 2 cm anterior to the site of RMT acquisition. The rTMS protocol will be as follows: each session will consist of 1-Hz rTMS over the dPMC for 30 minutes (1800 pulses) at 90% of the RMT. Patients will receive 4 sessions per day for 4 consecutive days with a 10-minute break between each session. Daily duration of the rTMS protocol, including breaks, will last approximately 160 minutes


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date December 7, 2022
Est. primary completion date December 7, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - patients 18-85 years of age who receive regular botulinum toxin (BoNT) scheduled every 12 weeks, on stable optimized doses but with reported benefits lasting = 9 weeks for 2 consecutive cycles. Patents followed at our center routinely fill out a self-reported form to document the duration of benefits perceived with BoNT therapy. Participants will be allowed to continue oral medications that they are taking for dystonia concurrently but will not be allowed to change their concurrent medication regimen throughout the duration of the study. Exclusion Criteria: - Presence of metallic objects or neurostimulators in the brain - Pregnancy - History of active seizures or epilepsy - Patients with severe scoliosis or other gait impairment that will preclude them from participating in gait evaluation.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
rTMS
repetitive transcranial magnetic stimulation is a painless, noninvasive form of neurostimulation. This study uses an accelerated protocol in which the neurostimulation pulses are delivered in 4 sessions per day over 4 consecutive days (16 total sessions). Active or sham rTMS will be provided at 9 weeks following botox injections.

Locations

Country Name City State
United States University of Florida Health Norman Fixel Institute for Neurological Diseases Gainesville Florida

Sponsors (2)

Lead Sponsor Collaborator
University of Florida Dystonia Medical Research Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) This is an objective scale evaluating patients on a variety of features including maximal excursion, duration, effects of sensory trick, shoulder elevation, range of motion, and time. Scores range from 0 to 85 where a higher score indicates more severity. Up to 24 weeks
Secondary Beck Depression Inventory (BDI) This is a 21-question survey evaluating depression in patients on a 0 to 3 scale, with a minimum score of 0 and maximum score 63, and higher score indicating a higher level of depression. Up to 24 weeks
Secondary Trail-Making Test: Part A Patients are instructed to connect circles in ascending numerical order and are scored on how quickly they are able to complete the task. A longer amount of time indicates more severe cognitive impairment (in general, more than 78 seconds to complete Part A is considered impaired). Up to 24 weeks
Secondary Trail-Making Test Patients are instructed to connect circles in ascending numerical order and are scored on how quickly they are able to complete the task. A longer amount of time indicates more severe cognitive impairment (in general, more than 273 seconds to complete Part B is considered impaired). Up to 24 weeks
Secondary Wisconsin Card Sorting Task (WCST) This is a cognitive task that asks patients to sort cards based on color, number, and shape. Up to 24 weeks
Secondary Gait Assessment Patients will be asked to walk across the Zeno walkways system for dynamic stability index (ratio between single and double support time). Up to 24 weeks
Secondary Gait Assessment Patients will be asked to walk across the Zeno walkways system for temporal parameters Up to 24 weeks
Secondary Gait Assessment Patients will be asked to walk across the Zeno walkways system for spatial parameters Up to 24 weeks
Secondary High Density Electroencephalogram (EEG) The patient's electrical activity of the brain will be recorded at rest Up to 24 weeks
Secondary High Density Electroencephalogram (EEG) The patient's electrical activity of the brain will be recorded with maximal range of motion/excursion in six directions: up, down, left, right, left shoulder, right shoulder Up to 24 weeks
Secondary TMS measures: Short Interval Intracortical Inhibition (SICI) In a paired-pulse TMS paradigm, a subthreshold pulse will be provided followed by an interstimulus interval and then subsequent delivery of a suprathreshold pulse. When the interstimulus interval is short (1-4 msec), the ratio of MEP amplitudes produced by these two pulses is known as short interval intracortical inhibition (SICI). Up to 24 weeks
Secondary TMS measures: Motor Evoked Potential (MEP) A single-pulse of TMS will be targeted over the motor cortex to generate a motor evoked potential (MEP), which can be captured on EMG. Up to 24 weeks
Secondary TMS measures: Cortical Silent Period (CSP) A single-pulse of TMS will be targeted over the motor cortex and the rest of the EMG will be analyzed to assess the amount of time muscle activity remains silent following the MEP (also known as the cortical silent period). Up to 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT03617367 - Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS) Phase 3
Not yet recruiting NCT04057911 - A Trial of Non-invasive Stimulation in Cervical Dystonia N/A
Withdrawn NCT02180139 - tDCS in Cervical Dystonia N/A
Completed NCT00541905 - Daily Dystonia Practice - A Trial to Investigate NT 201, the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Cervical Dystonia Phase 4
Unknown status NCT00418925 - Efficacy of Dronabinol for the Treatment of Cervical Dystonia Phase 2
Not yet recruiting NCT05715138 - Comparison of Pallidal With Subthalamic Deep Brain Stimulation for Cervical Dystonia N/A
Completed NCT02959645 - Assessment of Brain Activities in Cervical Dystonia
Completed NCT02131467 - Safety and Tolerability of Perampanel in Cervical Dystonia Phase 1/Phase 2
Completed NCT03805152 - Abobotulinum Toxin and Neubotulinum Toxin Injection in Cerivical Dystonia Phase 3
Completed NCT04949594 - Relief of Pain in Patients With Cervical Dystonia Through the Use of Transcutaneous Electric Nerve Stimulation (TENS)
Recruiting NCT01664013 - The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients Phase 4
Completed NCT00210431 - Post Marketing Surveillance Study of Dysport
Completed NCT00447772 - Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia Phase 3
Completed NCT05157100 - Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia Phase 4
Completed NCT00257660 - Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia Phase 3
Completed NCT05103202 - Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin
Terminated NCT00760318 - Keppra for Cervical Dystonia Phase 2
Completed NCT00323765 - Plasticity in Cervical Dystonia N/A
Completed NCT04171258 - Clinical Trial to Compare the Safety and Efficacy of Botulax® Versus Botox® in Patients With Cervical Dystonia Phase 1
Completed NCT04849988 - A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia Phase 2